Juan Delgado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juan Delgado has a total of 584 co-authors. Here are the top co-authors by number of shared publications:
- Juan Antonio Pineda
Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, Spain
10 shared publications - Juan Macías
Carlos III Health Institute CIBERINFEC Madrid
10 shared publications Eduardo Lissen
Viral Hepatitis and AIDS Study Group, Department of Internal Medicine, and
6 shared publicationsRafael de la Rosa
Internal Medicine Service, Hospital San Juan de Dios del Aljarafe, Bormujos, Spain
6 shared publicationsE. Lissen
Grupo Estudio Hepatitis vírica y SIDA, Servicio de Medicina Interna, Hospital Universitario Virgen del Rocío, Avenida Manuel Siurot s/n, 41013 Seville, Spain
5 shared publications- Ezequiel Ruiz-Mateos
Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, CSIC, University of Seville, Seville, Spain
5 shared publications
Latest Publications
- 5 July 2025
- Published by Springer Nature in Journal of Ultrasound
- Vol. 28 (3) , 575-585
Percutaneous core needle biopsy guided by ultrasound: a narrative review
Ultrasound-guided core needle biopsy (CNB) is a highly effective technique for diagnosing tumoral and inflammatory/infectious diseases. The procedure provides real-time visualization of anatomical structures such as vessels and nerves, reducing complications and enhancing accuracy. Traditionally performed by interventional radiologists, CNB can also be safely and effectively conducted by another specialists, including general physicians, thanks to the widespread availability of Point-of-Care Ultrasound. This not only improves and expedites the diagnostic process but also facilitates access to minimally invasive interventions by clinical services, establishing ultrasound-guided CNB as an essential tool for general physicians.
- 5 July 2025
- Published by Springer Nature in Journal of Ultrasound
- Vol. 28 (3) , 575-585
Percutaneous core needle biopsy guided by ultrasound: a narrative review
Ultrasound-guided core needle biopsy (CNB) is a highly effective technique for diagnosing tumoral and inflammatory/infectious diseases. The procedure provides real-time visualization of anatomical structures such as vessels and nerves, reducing complications and enhancing accuracy. Traditionally performed by interventional radiologists, CNB can also be safely and effectively conducted by another specialists, including general physicians, thanks to the widespread availability of Point-of-Care Ultrasound. This not only improves and expedites the diagnostic process but also facilitates access to minimally invasive interventions by clinical services, establishing ultrasound-guided CNB as an essential tool for general physicians.
- Open Access
- 9 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (10) , 3315
Effectiveness of Urea and Tolvaptan in the Treatment of Hypotonic Hyponatremia
Objective: The objective of this study was to compare the effectiveness of urea and tolvaptan in the treatment of plasma sodium levels in patients with hypotonic hyponatremia. Methods: This was an observational, longitudinal, and retrospective study including all adult patients who received treatment with urea or tolvaptan for hypotonic hyponatremia from 1 April 2014 to 31 October 2023 at the Department of Internal Medicine, Virgen del Rocío University Hospital, Seville, Spain. Results: Forty-seven (55.3%) patients received urea and 38 (44.7%) tolvaptan. The drugs were prescribed for the treatment of syndrome of inappropriate antidiuresis (SIAD) in 59 (69.4%) patients. The mean blood sodium level at the start of treatment was 123.5 ± 6.2 mEq/L. Overall, 61.7% and 63.2% of patients treated with urea and tolvaptan, respectively, achieved a normal blood sodium level (p = 0.89), although the time to have their sodium levels corrected differed between both groups: 41.7 ± 76 days with urea and 21 ± 23.9 days with tolvaptan (p = 0.038). The following were significant in the multivariate study: Initial sodium value (p = 0.037), absolute sodium improvement (p = 0.041), and percentage sodium improvement (p = 0.033). Among patients with SIAD, 69.5% achieved a normal sodium level; this figure was 45.5% for patients with heart failure. Three patients reported side adverse events in the urea group and none in the tolvaptan group. Conclusions: Our data, reflecting real-world practice and follow-up of patients with hypotonic hyponatremia, suggest that both urea and tolvaptan are safe, well-tolerated, and have a similar effectiveness in correcting blood sodium levels in patients with hypotonic hyponatremia, overall and secondary to SIAD, though treatment with tolvaptan achieved this goal earlier than urea.
- 9 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (10) , 3315
Open AccessEffectiveness of Urea and Tolvaptan in the Treatment of Hypotonic Hyponatremia
Objective: The objective of this study was to compare the effectiveness of urea and tolvaptan in the treatment of plasma sodium levels in patients with hypotonic hyponatremia. Methods: This was an observational, longitudinal, and retrospective study including all adult patients who received treatment with urea or tolvaptan for hypotonic hyponatremia from 1 April 2014 to 31 October 2023 at the Department of Internal Medicine, Virgen del Rocío University Hospital, Seville, Spain. Results: Forty-seven (55.3%) patients received urea and 38 (44.7%) tolvaptan. The drugs were prescribed for the treatment of syndrome of inappropriate antidiuresis (SIAD) in 59 (69.4%) patients. The mean blood sodium level at the start of treatment was 123.5 ± 6.2 mEq/L. Overall, 61.7% and 63.2% of patients treated with urea and tolvaptan, respectively, achieved a normal blood sodium level (p = 0.89), although the time to have their sodium levels corrected differed between both groups: 41.7 ± 76 days with urea and 21 ± 23.9 days with tolvaptan (p = 0.038). The following were significant in the multivariate study: Initial sodium value (p = 0.037), absolute sodium improvement (p = 0.041), and percentage sodium improvement (p = 0.033). Among patients with SIAD, 69.5% achieved a normal sodium level; this figure was 45.5% for patients with heart failure. Three patients reported side adverse events in the urea group and none in the tolvaptan group. Conclusions: Our data, reflecting real-world practice and follow-up of patients with hypotonic hyponatremia, suggest that both urea and tolvaptan are safe, well-tolerated, and have a similar effectiveness in correcting blood sodium levels in patients with hypotonic hyponatremia, overall and secondary to SIAD, though treatment with tolvaptan achieved this goal earlier than urea.
- 10 April 2025
- Published by Elsevier in Revista Clínica Española
- Vol. 225 (5)
Alta rentabilidad diagnóstica de la biopsia con aguja gruesa ecoguiada de adenopatías realizada en un servicio de medicina interna
- 10 April 2025
- Published by Elsevier in Revista Clínica Española
- Vol. 225 (5)
Alta rentabilidad diagnóstica de la biopsia con aguja gruesa ecoguiada de adenopatías realizada en un servicio de medicina interna
- 28 March 2025
- Published by Elsevier in Revista Clínica Española (English Edition)
- Vol. 225 (5) , 502282
High diagnostic yield of ultrasound-guided core needle biopsy of lymphadenopathy performed in an internal medicine department
- 28 March 2025
- Published by Elsevier in Revista Clínica Española (English Edition)
- Vol. 225 (5) , 502282
High diagnostic yield of ultrasound-guided core needle biopsy of lymphadenopathy performed in an internal medicine department
- Open Access
- 10 November 2023
- Published by Excellent Publishers in International Journal of Current Microbiology and Applied Sciences
- Vol. 12 (11) , 89-113
Banana (Musa AAA cv Williams) Response to Biological and Chemical Nematicides and their Rotation
The effect of different biological and chemical nematicide cycles per year or their alternation was compared on banana (Musa AAA cv. Williams) root weight, root nematode control and crop yield in a commercial banana plantation in Ecuador testing 11 treatments in a randomized complete block design with five replicates. Treatments consisted of the rotation of two or three chemicals or even the rotation of four biological nematicide cycles by year or the rotation of chemical and biological nematicides in the year plus the untreated control. Averaging the 24 root nematode samplings, the rotation of two and three chemical nematicide cycles by year reduced R. similis (P= 0.0347) by 25 and 23%, Helicotylenchus spp. (P= 0.0009) by 31 and 18% and total nematodes (P= 0.0074) by 28 and 21%, respectively. The rotation of four biological nematicide cycles by year drops R. similis between 10 and 28%, Helicotylenchus spp. between 5 and 21% and total nematode between 5 and 23%. Although there is substantial, positive literature on nematode control with biological products, for us is the first time that some reduction was observed. Given the COVID-19 pandemic, it was not possible to do successive harvests, but at the final harvest, from 23 to 25 months after first treatment application, a difference in yield (P< 0.0001) was observed. The highest number of boxes per hectare per year was found in the treatment with 4 cycles by year of SeaMaxx® + Cronox® with 4149 followed closely by two chemical nematicides cycles by year with 4122 boxes of 18.14 kg. The additional net income in the treatments that increased yield, deducted the cost of packing for each additional box and the treatment cost was between US $327 and $3420 ha-1 year-1 24 months after the first treatment was applied. However, the net profit for every dollar invested in nematode control was higher with two chemical nematicides with $20.2 compared to $6.9 returned for the four cycles of SeaMaxx® + Cronox® due to frequent of application and higher treatment cost.
- 10 November 2023
- Published by Excellent Publishers in International Journal of Current Microbiology and Applied Sciences
- Vol. 12 (11) , 89-113
Open AccessBanana (Musa AAA cv Williams) Response to Biological and Chemical Nematicides and their Rotation
The effect of different biological and chemical nematicide cycles per year or their alternation was compared on banana (Musa AAA cv. Williams) root weight, root nematode control and crop yield in a commercial banana plantation in Ecuador testing 11 treatments in a randomized complete block design with five replicates. Treatments consisted of the rotation of two or three chemicals or even the rotation of four biological nematicide cycles by year or the rotation of chemical and biological nematicides in the year plus the untreated control. Averaging the 24 root nematode samplings, the rotation of two and three chemical nematicide cycles by year reduced R. similis (P= 0.0347) by 25 and 23%, Helicotylenchus spp. (P= 0.0009) by 31 and 18% and total nematodes (P= 0.0074) by 28 and 21%, respectively. The rotation of four biological nematicide cycles by year drops R. similis between 10 and 28%, Helicotylenchus spp. between 5 and 21% and total nematode between 5 and 23%. Although there is substantial, positive literature on nematode control with biological products, for us is the first time that some reduction was observed. Given the COVID-19 pandemic, it was not possible to do successive harvests, but at the final harvest, from 23 to 25 months after first treatment application, a difference in yield (P< 0.0001) was observed. The highest number of boxes per hectare per year was found in the treatment with 4 cycles by year of SeaMaxx® + Cronox® with 4149 followed closely by two chemical nematicides cycles by year with 4122 boxes of 18.14 kg. The additional net income in the treatments that increased yield, deducted the cost of packing for each additional box and the treatment cost was between US $327 and $3420 ha-1 year-1 24 months after the first treatment was applied. However, the net profit for every dollar invested in nematode control was higher with two chemical nematicides with $20.2 compared to $6.9 returned for the four cycles of SeaMaxx® + Cronox® due to frequent of application and higher treatment cost.
- 29 November 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 17 (3) , 761-775
Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry
Acetylsalicylic acid (ASA) is widely used in the treatment and prevention of cardiovascular disorders. Our objective is to evaluate its possible protective role, not only in mortality but also in other aspects such as inflammation, symptomatic thrombosis, and intensive care unit (ICU) admission in hospitalized COVID-19 patients. We realized an observational retrospective cohort study of 20,641 patients with COVID-19 pneumonia collected and followed-up from Mar 1st, 2020 to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Propensity score matching (PSM) was performed to determine whether treatment with ASA affected outcomes in COVID-19 patients. On hospital admission, 3291 (15.9%) patients were receiving ASA. After PSM, 3291 patients exposed to ASA and 2885 not-exposed patients were analyzed. In-hospital mortality was higher in the ASA group (30.4 vs. 16.9%, p < 0.001) in the global sample. After PSM, no differences were found between groups (30.4 vs. 30.3%, p = 0.938). There were no differences in inflammation, symptomatic thrombosis, or ICU admission. In conclusion, ASA intake is not associated with in-hospital mortality or any other health outcome evaluated after applying PSM analysis in a real-world large sample of hospitalized COVID-19 patients.
- 29 November 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 17 (3) , 761-775
Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry
Acetylsalicylic acid (ASA) is widely used in the treatment and prevention of cardiovascular disorders. Our objective is to evaluate its possible protective role, not only in mortality but also in other aspects such as inflammation, symptomatic thrombosis, and intensive care unit (ICU) admission in hospitalized COVID-19 patients. We realized an observational retrospective cohort study of 20,641 patients with COVID-19 pneumonia collected and followed-up from Mar 1st, 2020 to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Propensity score matching (PSM) was performed to determine whether treatment with ASA affected outcomes in COVID-19 patients. On hospital admission, 3291 (15.9%) patients were receiving ASA. After PSM, 3291 patients exposed to ASA and 2885 not-exposed patients were analyzed. In-hospital mortality was higher in the ASA group (30.4 vs. 16.9%, p < 0.001) in the global sample. After PSM, no differences were found between groups (30.4 vs. 30.3%, p = 0.938). There were no differences in inflammation, symptomatic thrombosis, or ICU admission. In conclusion, ASA intake is not associated with in-hospital mortality or any other health outcome evaluated after applying PSM analysis in a real-world large sample of hospitalized COVID-19 patients.
- Open Access
- 13 October 2021
- Published by MDPI AG in Journal of Fungi
- Vol. 7 (10) , 856
Update on Dihydropteroate Synthase (DHPS) Mutations in Pneumocystis jirovecii
A Pneumocystis jirovecii is one of the most important microorganisms that cause pneumonia in immunosupressed individuals. The guideline for treatment and prophylaxis of Pneumocystis pneumonia (PcP) is the use of a combination of sulfa drug-containing trimethroprim and sulfamethoxazole. In the absence of a reliable method to culture Pneumocystis, molecular techniques have been developed to detect mutations in the dihydropteroate synthase gene, the target of sulfa drugs, where mutations are related to sulfa resistance in other microorganisms. The presence of dihydropteroate synthase (DHPS) mutations has been described at codon 55 and 57 and found almost around the world. In the current work, we analyzed the most common methods to identify these mutations, their geographical distribution around the world, and their clinical implications. In addition, we describe new emerging DHPS mutations. Other aspects, such as the possibility of transmitting Pneumocystis mutated organisms between susceptible patients is also described, as well as a brief summary of approaches to study these mutations in a heterologous expression system.
- 13 October 2021
- Published by MDPI AG in Journal of Fungi
- Vol. 7 (10) , 856
Open AccessUpdate on Dihydropteroate Synthase (DHPS) Mutations in Pneumocystis jirovecii
A Pneumocystis jirovecii is one of the most important microorganisms that cause pneumonia in immunosupressed individuals. The guideline for treatment and prophylaxis of Pneumocystis pneumonia (PcP) is the use of a combination of sulfa drug-containing trimethroprim and sulfamethoxazole. In the absence of a reliable method to culture Pneumocystis, molecular techniques have been developed to detect mutations in the dihydropteroate synthase gene, the target of sulfa drugs, where mutations are related to sulfa resistance in other microorganisms. The presence of dihydropteroate synthase (DHPS) mutations has been described at codon 55 and 57 and found almost around the world. In the current work, we analyzed the most common methods to identify these mutations, their geographical distribution around the world, and their clinical implications. In addition, we describe new emerging DHPS mutations. Other aspects, such as the possibility of transmitting Pneumocystis mutated organisms between susceptible patients is also described, as well as a brief summary of approaches to study these mutations in a heterologous expression system.
- Open Access
Detailed stratified GWAS analysis for severe COVID-19 in four European populations
Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our understanding of underlying disease mechanisms. Here, we describe an extended GWAS meta-analysis of a well-characterized cohort of 3,260 COVID-19 patients with respiratory failure and 12,483 population controls from Italy, Spain, Norway and Germany/Austria, including stratified analyses based on age, sex and disease severity, as well as targeted analyses of chromosome Y haplotypes, the human leukocyte antigen (HLA) region and the SARS-CoV-2 peptidome. By inversion imputation, we traced a reported association at 17q21.31 to a highly pleiotropic ∼0.9-Mb inversion polymorphism and characterized the potential effects of the inversion in detail. Our data, together with the 5 th release of summary statistics from the COVID-19 Host Genetics Initiative, also identified a new locus at 19q13.33, including NAPSA , a gene which is expressed primarily in alveolar cells responsible for gas exchange in the lung.
Open AccessDetailed stratified GWAS analysis for severe COVID-19 in four European populations
Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our understanding of underlying disease mechanisms. Here, we describe an extended GWAS meta-analysis of a well-characterized cohort of 3,260 COVID-19 patients with respiratory failure and 12,483 population controls from Italy, Spain, Norway and Germany/Austria, including stratified analyses based on age, sex and disease severity, as well as targeted analyses of chromosome Y haplotypes, the human leukocyte antigen (HLA) region and the SARS-CoV-2 peptidome. By inversion imputation, we traced a reported association at 17q21.31 to a highly pleiotropic ∼0.9-Mb inversion polymorphism and characterized the potential effects of the inversion in detail. Our data, together with the 5 th release of summary statistics from the COVID-19 Host Genetics Initiative, also identified a new locus at 19q13.33, including NAPSA , a gene which is expressed primarily in alveolar cells responsible for gas exchange in the lung.
- 1 November 2020
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 91, 104240
Death risk stratification in elderly patients with covid-19. A comparative cohort study in nursing homes outbreaks
- 1 November 2020
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 91, 104240
Death risk stratification in elderly patients with covid-19. A comparative cohort study in nursing homes outbreaks